12 Month Price Forecast For LLY
Distance to LLY Price Forecasts
LLY Price Momentum
๐ค Considering Eli Lilly (LLY)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 10:21 AM UTC
LLY Analyst Ratings & Price Targets
Based on our analysis of 38 Wall Street analysts, LLY has a bullish consensus with a median price target of $1,000.00 (ranging from $620.00 to $1,190.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $868.88, the median forecast implies a 15.1% upside. This outlook is supported by 21 Buy, 6 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Peter Verdult at Citigroup, projecting a 37.0% upside. Conversely, the most conservative target is provided by David Toung at Argus Research, suggesting a 28.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LLY Analyst Consensus
LLY Price Target Range
Latest LLY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LLY.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Feb 3, 2025 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $1,038.00 |
Jan 28, 2025 | Wells Fargo | Mohit Bansal | Overweight | Maintains | $970.00 |
Jan 28, 2025 | Citigroup | Peter Verdult | Buy | Maintains | $1,190.00 |
Dec 10, 2024 | B of A Securities | Tim Anderson | Buy | Reinstates | $997.00 |
Nov 15, 2024 | Wolfe Research | Alexandria Hammond | Outperform | Initiates | $1,000.00 |
Nov 4, 2024 | Deutsche Bank | James Shin | Buy | Maintains | $1,015.00 |
Oct 31, 2024 | Barclays | Carter Gould | Overweight | Maintains | $975.00 |
Oct 31, 2024 | B of A Securities | Geoff Meacham | Buy | Maintains | $1,100.00 |
Oct 25, 2024 | Citigroup | Peter Verdult | Buy | Maintains | $1,250.00 |
Oct 17, 2024 | Bernstein | Outperform | Initiates | $1,100.00 | |
Oct 10, 2024 | Truist Securities | Srikripa Devarakonda | Buy | Maintains | $1,033.00 |
Oct 3, 2024 | Deutsche Bank | James Shin | Buy | Reiterates | $1,025.00 |
Sep 16, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $885.00 |
Sep 13, 2024 | Citigroup | Peter Verdult | Buy | Reinstates | $1,060.00 |
Sep 13, 2024 | JP Morgan | Chris Schott | Overweight | Maintains | $1,100.00 |
Sep 9, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $885.00 |
Aug 27, 2024 | Morgan Stanley | Terence Flynn | Overweight | Reiterates | $1,106.00 |
Aug 19, 2024 | Cantor Fitzgerald | Louise Chen | Overweight | Reiterates | $885.00 |
Aug 16, 2024 | Guggenheim | Seamus Fernandez | Buy | Maintains | $1,030.00 |
Aug 14, 2024 | Berenberg | Kerry Holford | Buy | Maintains | $1,050.00 |
Stocks Similar to Eli Lilly & Co
The following stocks are similar to Eli Lilly based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Eli Lilly & Co (LLY) Financial Data
Eli Lilly & Co has a market capitalization of $775.79B with a P/E ratio of 73.9x. The company generates $40.86B in trailing twelve-month revenue with a 20.5% profit margin.
Revenue growth is +20.4% quarter-over-quarter, while maintaining an operating margin of +39.8% and return on equity of +65.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Eli Lilly & Co (LLY) Company Overview
About Eli Lilly & Co
Develops and markets human pharmaceuticals globally.
The company generates revenue by discovering, developing, and marketing a diverse range of pharmaceuticals across multiple therapeutic areas, including diabetes, oncology, autoimmune diseases, and mental health. Its product portfolio includes well-known medications for chronic conditions, which are sold worldwide, and the company also invests in research and development to innovate and expand its offerings.
Eli Lilly operates the Lilly Seaport Innovation Center in Boston, focusing on RNA and DNA-based therapies, and has established collaborations with several leading pharmaceutical companies and research institutions to enhance drug development capabilities. Founded in 1876 and headquartered in Indianapolis, Indiana, the company has a long-standing history in the pharmaceutical sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
43,000
CEO
Mr. David A. Ricks
Country
United States
IPO Year
1972
Website
www.lilly.comEli Lilly & Co (LLY) Latest News & Analysis
Zacks.com users are increasingly focused on Lilly (LLY), indicating potential interest and movement in the stock. Investors may want to monitor developments closely.
Increased interest in Lilly (LLY) could signal potential price movement or volatility, influencing investment strategies and portfolio decisions.
OliX and Lilly Enter Global Licensing Agreement for MASH and Other Cardiometabolic Indications
1 day agoOliX and Eli Lilly have entered a global licensing agreement for the development and commercialization of OLX75016, targeting cardiometabolic indications.
The licensing agreement between OliX and Eli Lilly signals potential growth in cardiometabolic treatments, likely boosting investor confidence and interest in both companies' stock performance.
Identifying stocks that could potentially double in value within three years is challenging, even during the current bull market.
The mention of potential for significant stock gains highlights investment opportunities, indicating market optimism but also the challenges in identifying high-growth stocks.
MarketBeat monitors top-rated Wall Street analysts and their stock recommendations, providing insights into best-performing stocks for investors.
MarketBeat's tracking of top analysts highlights stocks with strong recommendations, aiding investors in identifying potential high-performing investments.
Growth stocks outside the AI sector, particularly in healthcare, are gaining attention and may present investment opportunities.
Diversifying beyond AI into other sectors like healthcare can uncover undervalued growth stocks, potentially leading to better returns and reduced risk in investment portfolios.
Frequently Asked Questions About LLY Stock
What is Eli Lilly & Co's (LLY) stock forecast for 2025?
Based on our analysis of 38 Wall Street analysts, Eli Lilly & Co (LLY) has a median price target of $1,000.00. The highest price target is $1,190.00 and the lowest is $620.00.
Is LLY stock a good investment in 2025?
According to current analyst ratings, LLY has 21 Buy ratings, 6 Hold ratings, and 1 Sell ratings. The stock is currently trading at $868.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for LLY stock?
Wall Street analysts predict LLY stock could reach $1,000.00 in the next 12 months. This represents a 15.1% increase from the current price of $868.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Eli Lilly & Co's business model?
The company generates revenue by discovering, developing, and marketing a diverse range of pharmaceuticals across multiple therapeutic areas, including diabetes, oncology, autoimmune diseases, and mental health. Its product portfolio includes well-known medications for chronic conditions, which are sold worldwide, and the company also invests in research and development to innovate and expand its offerings.
What is the highest forecasted price for LLY Eli Lilly & Co?
The highest price target for LLY is $1,190.00 from Peter Verdult at Citigroup, which represents a 37.0% increase from the current price of $868.88.
What is the lowest forecasted price for LLY Eli Lilly & Co?
The lowest price target for LLY is $620.00 from David Toung at Argus Research, which represents a -28.6% decrease from the current price of $868.88.
What is the overall LLY consensus from analysts for Eli Lilly & Co?
The overall analyst consensus for LLY is bullish. Out of 38 Wall Street analysts, 21 rate it as Buy, 6 as Hold, and 1 as Sell, with a median price target of $1,000.00.
How accurate are LLY stock price projections?
Stock price projections, including those for Eli Lilly & Co, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.